Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02419508 · ClinicalTrials.gov registry record · Phase 4
SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 290
- Enrollment target
NCT02419508 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 290 participants.
The verdict
NCT02419508, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 290 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension
- DRUG Brinz/brim vehicle
- DRUG Prostaglandin analogue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2015-08-07 |
| Est. Completion | 2018-02-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02419508
The ClinicalTrials.gov registry entry for NCT02419508 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension is the first listed.
NCT02419508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02419508 about?
NCT02419508 is a clinical study titled "SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)". The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT02419508?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 290 participants. The study started on 2015-08-07. Estimated completion is 2018-02-27.
What interventions are being tested in trial NCT02419508?
The interventions under investigation include: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension (DRUG), Brinz/brim vehicle (DRUG), Prostaglandin analogue (DRUG).
Who is sponsoring clinical trial NCT02419508?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.